CC
The Chemours Company
NYSE · Basic Materials · Chemicals - Specialty · US
$15.37
−0.71%Year over year
Reported trailing growth
- Revenue
- -1.4%
- EBITDA
- —
- EBIT
- —
- EPS
- +28.6%
- Free cash flow
- +331.5%
- Operating cash flow
- +36.8%
Forward estimates
Based on analyst estimates
- Revenue
- +5.6%
- EBITDA
- +630.6%
- EPS
- +178.6%
Three-year CAGR
- Revenue
- -5.3%
- EBITDA
- -34.7%
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -51.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026